Grant: Doctoral: Vanier Canada Graduate Scholarships
University of Toronto
$150,000.00
"In vitro" modeling of the cooperation between oncogenes and tumor suppressors promoting carcinogenesis in pancreatic adenocarcinoma
FY 2008-09
Summary
Pancreatic cancer is the fourth leading cause of cancer death in North America with an overall 5 year survival rate of 2-3%. Early detection and chemoprevention are the best strategies to reduce mortality for this cancer type. This would be best achieved by a comprehensive understanding of the molecular aberrations that occur during the early stages of pancreatic duct cell carcinogenesis. Infiltrating pancreatic cancer putatively evolves from histologically well-defined precursor lesions in the pancreatic ductal epithelium termed Pancreatic Intraepithelial Neoplasias (PanINs). Molecular screening of genetic aberrations in PanIN lesions has revealed a multi-stage pattern of pancreatic ductal carcinogenesis, which includes activation of proto-oncogenes and inactivation of tumor suppressor genes (TSGs). In pancreatic duct adenocarcinoma (PDA), activation of the KRAS oncogene has been observed in 95% of cases, while the inactivation of TSGs including SMAD4, p53, and p16 occurs in 55%, 75%, and 100% of cases, respectively. The dynamics of how these aberrations contribute to carcinogenesis remain largely speculative. In this project I will be providing a model for PDA by transforming human pancreatic duct cells with multiple genetic changes. My first approach will be to study the synergy between the known tumor suppressor p16 with KRAS oncogene in HPDE cells. We will be suppressing the expression of p16 and upregulating the oncogenic form of KRAS protein in the pancreatic duct epithelial cell line, HPDE. In addition, we will use a combination of shRNA library and chromosome genomic hybridization techniques to identify novel candidate TSGs that cooperate with KRAS to promote PDA. This in vitro model of multi genetic aberrations has the potential clinical implication of finding markers that can identify pancreatic cancer at an earlier stage, or identifying targets that can be used for treatment.
Department
Program
Doctoral: Vanier Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
184583
Name
Radulovich Nikolina
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
"In vitro" modeling of the cooperation between oncogenes and tumor suppressors promoting carcinogenesis in pancreatic adenocarcinoma
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Cell-Cycle Regulation; K-Ras Oncogene; Mouse Models Of Disease; P16/P14 Tumor Suppressor; Pancreatic Cancer Biology; Quantitative Real Time Polymerase Chain Reaction; Shrna And Cdna Lentiviral Gene Expression; Shrna Library Screening; Tumor Biology; Viral And Mammalian Cell Culture
Abstract
Pancreatic cancer is the fourth leading cause of cancer death in North America with an overall 5 year survival rate of 2-3%. Early detection and chemoprevention are the best strategies to reduce mortality for this cancer type. This would be best achieved by a comprehensive understanding of the molecular aberrations that occur during the early stages of pancreatic duct cell carcinogenesis. Infiltrating pancreatic cancer putatively evolves from histologically well-defined precursor lesions in the pancreatic ductal epithelium termed Pancreatic Intraepithelial Neoplasias (PanINs). Molecular screening of genetic aberrations in PanIN lesions has revealed a multi-stage pattern of pancreatic ductal carcinogenesis, which includes activation of proto-oncogenes and inactivation of tumor suppressor genes (TSGs). In pancreatic duct adenocarcinoma (PDA), activation of the KRAS oncogene has been observed in 95% of cases, while the inactivation of TSGs including SMAD4, p53, and p16 occurs in 55%, 75%, and 100% of cases, respectively. The dynamics of how these aberrations contribute to carcinogenesis remain largely speculative. In this project I will be providing a model for PDA by transforming human pancreatic duct cells with multiple genetic changes. My first approach will be to study the synergy between the known tumor suppressor p16 with KRAS oncogene in HPDE cells. We will be suppressing the expression of p16 and upregulating the oncogenic form of KRAS protein in the pancreatic duct epithelial cell line, HPDE. In addition, we will use a combination of shRNA library and chromosome genomic hybridization techniques to identify novel candidate TSGs that cooperate with KRAS to promote PDA. This in vitro model of multi genetic aberrations has the potential clinical implication of finding markers that can identify pancreatic cancer at an earlier stage, or identifying targets that can be used for treatment.
Competitiondate
200811
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Radulovich, Nikolina
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~